On July 31, 10x Genomics, Inc. fell 5.45% in regular trading, at $46.71/share, with turnover of $30.859 million. The decline came amid broad-based selling pressure across the Life Sciences Tools and Services sector, with multiple peer names posting notable losses in the same session.

Among sector peers, Illumina fell 5.4%, Thermo Fisher Scientific fell 2.08%, Tempus AI fell 2.53%, and Danaher fell 1.64%, while Bio-Techne was essentially flat at +0.06%. The sector-wide weakness dragged 10x Genomics lower despite a constructive fundamental backdrop heading into its August 6 earnings report, for which consensus expects revenue of approximately $147 million (up 5.28% year-over-year) and adjusted EPS of -$0.24. Earlier in July, BofA Securities had raised its price target on the stock from $30 to $46, and the company recently announced collaborations with Lausanne University Hospital and Cleveland Clinic to advance single-cell and spatial technologies in cancer diagnostics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)